Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence
Abstract
1. Introduction
2. Background—Thematic Analysis
2.1. SA-AKI
2.2. PSP Kinetics and Serial Measurements
2.3. PSP in Renal Physiology and Pathophysiology
2.4. Diagnostic Accuracy of PSP vs. Procalcitonin (PCT)
2.5. PSP in Sepsis Without AKI
2.6. PSP in AKI Without Sepsis
2.7. Cutoff Values for Sepsis Diagnosis
2.8. PSP in SA-AKI
2.9. Cutoff Values for SA-AKI Diagnosis
2.10. PSP and Hemodialysis
2.11. Prognosis—Survival and Mortality
3. Methodology
3.1. Study Type
3.2. Search Strategy
3.3. Eligibility
3.3.1. Inclusion Criteria
3.3.2. Exclusion Criteria
3.4. Selection of Studies
3.5. Data Extraction and Analysis
3.6. Ethical Considerations
3.7. Selected Studies
4. Results
5. Discussion
6. Future Prospects
7. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Rhee, C.; Dantes, R.; Epstein, L.; Murphy, D.J.; Seymour, C.W.; Iwashyna, T.J.; Kadri, S.S.; Angus, D.C.; Danner, R.L.; Fiore, A.E.; et al. CDCPrevention Epicenter Program Incidence Trends of Sepsis in USHospitals Using Clinical vs Claims Data 2009–2014. JAMA 2017, 318, 1241–1249. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Dyck, B.; Unterberg, M.; Adamzik, M.; Koos, B. The Impact of Pathogens on Sepsis Prevalence and Outcome. Pathogens 2024, 13, 89. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara, D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet 2020, 395, 200–211. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ye, C.; Zhu, C.; Hu, S.; Mei, Y.; Yang, T. A study on the factors influencing mortality risk in sepsis-induced acute kidney injury based on analysis of the MIMIC database. Clin. Exp. Med. 2025, 25, 192. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Lachmann, G.; Reinhart, K. The History of Biomarkers: How Far Have We Come? Crit. Care Clin. 2020, 36, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, G.S.; Frota, M.L.; Gonzaga, M.J.D.; Vattimo, M.F.F.; Lima, C. The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury. Biomedicines 2024, 12, 931. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kustán, P.; Horváth-Szalai, Z.; Mühl, D. Nonconventional Markers of Sepsis. EJIFCC 2017, 28, 122–133. [Google Scholar] [PubMed] [PubMed Central]
- Kouroupis, D.; Zografou, I.; Doukelis, P.; Patoulias, D.; Popovic, D.S.; Karakasis, P.; Pyrpasopoulou, A.; Stavropoulos, K.; Papadopoulos, C.; Giouleme, O.; et al. Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders. J. Pers. Med. 2025, 15, 125. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Yaegashi, Y.; Shirakawa, K.; Sato, N.; Suzuki, Y.; Kojika, M.; Imai, S.; Takahashi, G.; Miyata, M.; Furusako, S.; Endo, S. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J. Infect. Chemother. 2005, 11, 234–238. [Google Scholar] [CrossRef] [PubMed]
- Masson, S.; Caironi, P.; Fanizza, C.; Thomae, R.; Bernasconi, R.; Noto, A.; Oggioni, R.; Pasetti, G.S.; Romero, M.; Tognoni, G.; et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: Data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015, 41, 12–20. [Google Scholar] [CrossRef]
- Kyriazopoulou, E.; Leventogiannis, K.; Tavoulareas, G.; Mainas, E.; Toutouzas, K.; Mathas, C.; Prekates, A.; Sakka, V.; Panagopoulos, P.; Syrigos, K.; et al. Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19. Sci. Rep. 2023, 13, 3814. [Google Scholar] [CrossRef] [PubMed]
- Ackland, G.L.; Prowle, J.R. Presepsin: Solving a soluble (CD14) problem in sepsis? Intensive Care Med. 2015, 41, 351–353. [Google Scholar] [CrossRef] [PubMed]
- Jersmann, H.P. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol. Cell Biol. 2005, 83, 462–467. [Google Scholar] [CrossRef]
- Egi, M.; Ogura, H.; Yatabe, T.; Atagi, K.; Inoue, S.; Iba, T.; Kakihana, Y.; Kawasaki, T.; Kushimoto, S.; Kuroda, Y.; et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020). J. Intensive Care 2021, 9, 53. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Nagata, T.; Yasuda, Y.; Ando, M.; Abe, T.; Katsuno, T.; Kato, S.; Tsuboi, N.; Matsuo, S.; Maruyama, S. Clinical impact of kidney function on presepsin levels. PLoS ONE 2015, 10, e0129159. [Google Scholar] [CrossRef]
- Nakamura, Y.; Ishikura, H.; Nishida, T.; Kawano, Y.; Yuge, R.; Ichiki, R.; Murai, A. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol. 2014, 14, 88. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Schrier, R.W.; Wang, W. Acute renal failure and sepsis. N. Engl. J. Med. 2004, 351, 159–169. [Google Scholar] [CrossRef] [PubMed]
- Umbro, I.; Gentile, G.; Tinti, F.; Muiesan, P.; Mitterhofer, A.P. Recent advances in pathophysiology and biomarkers of sepsis-induced acute kidney injury. J. Infect. 2016, 72, 131–142. [Google Scholar] [CrossRef] [PubMed]
- May, C.N.; Ishikawa, K.; Wan, L.; Williams, J.; Wellard, R.M.; Pell, G.S.; Jackson, G.D.; Bellomo, R. Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion. Intensive Care Med. 2012, 38, 886–893. [Google Scholar] [CrossRef] [PubMed]
- Porta, F.; Takala, J.; Weikert, C.; Bracht, H.; Kolarova, A.; Lauterburg, B.H.; Borotto, E.; Jakob, S.M. Effects of prolonged endotoxemia on liver, skeletal muscle and kidney mitochondrial function. Crit. Care 2006, 10, R118. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Gomez, H.; Ince, C.; De Backer, D.; Pickkers, P.; Payen, D.; Hotchkiss, J.; Kellum, J.A. A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014, 41, 3–11. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Pettilä, V.; Bellomo, R. Understanding acute kidney injury in sepsis. Intensive Care Med. 2014, 40, 1018–1020. [Google Scholar] [CrossRef] [PubMed]
- Zarbock, A.; Nadim, M.K.; Pickkers, P.; Gomez, H.; Bell, S.; Joannidis, M.; Kashani, K.; Koyner, J.L.; Pannu, N.; Meersch, M.; et al. Sepsis-associated acute kidney injury: Consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat. Rev. Nephrol. 2023, 19, 401–417. [Google Scholar] [CrossRef] [PubMed]
- Peerapornratana, S.; Manrique-Caballero, C.L.; Gómez, H.; Kellum, J.A. Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019, 96, 1083–1099. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Fischer, P.; Grigoras, C.; Bugariu, A.; Nicoara-Farcau, O.; Stefanescu, H.; Benea, A.; Hadade, A.; Margarit, S.; Sparchez, Z.; Tantau, M.; et al. Are presepsin and resistin better markers for bacterial infection in patients with decompensated liver cirrhosis? Dig. Liver Dis. 2019, 51, 1685–1691. [Google Scholar] [CrossRef] [PubMed]
- Fujii, E.; Fujino, K.; Eguchi, Y. An evaluation of clinical inflammatory and coagulation markers in patients with sepsis: A pilot study. Acute Med. Surg. 2019, 6, 158–164. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kotera, A.; Sagishima, K.; Tashiro, T.; Niimori, D.; Kamohara, H.; Kinoshita, Y. A validation of presepsin levels in kidney dysfunction patients: Four case reports. J. Intensive Care 2014, 2, 63. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ali, F.T.; Ali, M.A.; Elnakeeb, M.M.; Bendary, H.N. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin. Chim. Acta 2016, 460, 93–101. [Google Scholar] [CrossRef] [PubMed]
- Lee, G.B.; Lee, J.W.; Yoon, S.H.; Hwang, W.M.; Yun, S.R.; Koh, D.H.; Park, Y. Plasma presepsin for mortality prediction in patients with sepsis-associated acute kidney injury requiring continuous kidney replacement therapy. Kidney Res. Clin. Pract. 2024, 43, 457–468. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Puspitasari, S.; Semedi, B.P.; Rehatta, N.M.; Maulydia, M.; Purnomo, W. Comparison of kidney injury molecule-1, proenkephalin and presepsin as predictors of diagnostics and severity of sepsis associated acute kidney injury. Edelweiss Appl. Sci. Technol. 2025, 9, 331–342. [Google Scholar] [CrossRef]
- Kang, T.; Yoo, J.; Choi, H.; Lee, S.; Jekarl, D.W.; Kim, Y. Performance evaluation of presepsin using a Sysmex HISCL-5000 analyzer and determination of reference interval. J. Clin. Lab. Anal. 2022, 36, e24618. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Han, S.; Kim, M.J.; Ko, H.J.; Lee, E.J.; Kim, H.R.; Jeon, J.W.; Ham, Y.R.; Na, K.R.; Lee, K.W.; Lee, S.I.; et al. Diagnostic and Prognostic Roles of C-Reactive Protein, Procalcitonin, and Presepsin in Acute Kidney Injury Patients Initiating Continuous Renal Replacement Therapy. Diagnostics 2023, 13, 777. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Miyoshi, M.; Inoue, Y.; Nishioka, M.; Ikegame, A.; Nakao, T.; Kishi, S.; Doi, T.; Nagai, K. Clinical evaluation of presepsin considering renal function. PLoS ONE 2019, 14, e0215791. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kobayashi, S.; Amano, H.; Terawaki, H.; Kawaguchi, Y.; Yokoo, T. Prediction of presepsin concentrations through commensurate decline in kidney function in the elderly. Clin. Chim. Acta 2020, 500, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Shozushima, T.; Takahaski, G.; Matsumoto, N.; Kojika, M.; Okamura, Y.; Endo, S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J. Infect. Chemother. 2011, 17, 764–769. [Google Scholar] [CrossRef]
- Sargentini, V.; Ceccarelli, G.; D’alessandro, M.; Collepardo, D.; Morelli, A.; D’egidio, A.; Mariotti, S.; Nicoletti, A.M.; Evangelista, B.; D’ettorre, G.; et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clin. Chem. Lab. Med. 2014, 53, 567–573. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.; Chen, Y.X.; Yin, Q.; Zhao, Y.Z.; Li, C.S. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit. Care. 2013, 17, R244. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kondo, Y.; Umemura, Y.; Hayashida, K.; Hara, Y.; Aihara, M.; Yamakawa, K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: A systematic review and meta-analysis. J. Intensive Care 2019, 7, 22. [Google Scholar] [CrossRef]
- Wu, J.; Hu, L.; Zhang, G.; Wu, F.; He, T. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10, e0133057. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ren, E.; Xiao, H.; Wang, G.; Zhao, Y.; Yu, H.; Li, C. Value of procalcitonin and presepsin in the diagnosis and severity stratification of sepsis and septic shock. World J. Emerg. Med. 2024, 15, 135–138. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zhang, X.; Liu, D.; Liu, Y.N.; Wang, R.; Xie, L.X. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: A meta-analysis. Crit. Care 2015, 19, 323. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Endo, S.; Suzuki, Y.; Takahashi, G.; Shozushima, T.; Ishikura, H.; Murai, A.; Nishida, T.; Irie, Y.; Miura, M.; Iguchi, H.; et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J. Infect. Chemother. 2012, 18, 891–897. [Google Scholar] [CrossRef] [PubMed]
- Godnic, M.; Stubjar, D.; Skvarc, M.; Jukic, T. Diagnostic and prognostic value of sCD14-ST—Presepsin for patients admitted to hospital intensive care unit (ICU). Wien. Klin. Wochenschr. 2015, 127, 521–527. [Google Scholar] [CrossRef] [PubMed]
- Arakawa, K.; Saeki, A.; Ide, R.; Matsushita, Y. Presepsin cut-off value for diagnosis of sepsis in patients with renal dysfunction. PLoS ONE 2022, 17, e0273930. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Dragoş, D.; Ghenu, M.I.; Timofte, D.; Balcangiu-Stroescu, A.E.; Ionescu, D.; Manea, M.M. The cutoff value of presepsin for diagnosing sepsis increases with kidney dysfunction, a cross-sectional observational study. Medicine 2023, 102, e32620. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Honore, P.M.; Jacobs, R.; Hendrickx, I.; De Waele, E.; Van Gorp, V.; Spapen, H.D. Presepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy: Will another promising biomarker bite the dust? Crit. Care 2015, 19, 428. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Honore, P.M.; Redant, S.; De Bels, D. Reliability of biomarkers of sepsis during extracorporeal therapies: The clinician needs to know what is eliminated and what is not. Crit. Care 2020, 24, 553. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Galeano, D.; Zanoli, L.; Fatuzzo, P.; Granata, A. Utilità dell’sCD14-ST per la diagnosi di sepsi nel paziente con insufficienza renale [Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure]. G. Ital. Nefrol. 2016, 33, gin/33.2.6. (In Italian) [Google Scholar] [PubMed]
- Shiota, J. Changes of Early Sepsis Biomarker Presepsin Level during Hemodialysis: Influence of β2-Microglobulin Clearance of Dialysis Membrane: A Preliminary Study. Kidney Dis. 2019, 5, 43–50. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Hwang, W.M.; Park, Y.; Yoon, S.H.; Yun, S.R.; Lim, D.M. Mortality prediction of plasma presepsin in sepsis-associated acute kidney injury patients requiring continuous kidney replacement therapy. Nephrol. Dial. Transplant. 2024, 39 (Suppl. S1), gfae069–1776. [Google Scholar] [CrossRef]
- Kwak, S.H.; Ahn, S.; Shin, M.H.; Lee, A.Y.; Lee, S.H.; Chung, K.; Kim, Y.S.; Lee, S.G.; Suk, M. ParkIdentification of Biomarkers for the Diagnosis of Sepsis-Associated Acute Kidney Injury and Prediction of Renal Recovery in the Intensive Care Unit. Yonsei Med. J. 2023, 64, 181–190. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, G.; Shibata, S.; Fukui, Y.; Okamura, Y.; Inoue, Y. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn. Microbiol. Infect. Dis. 2016, 86, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Shimoyama, Y.; Umegaki, O.; Kadono, N.; Minami, T. Presepsin and prognostic nutritional index are predictors of septic acute kidney injury, renal replacement therapy initiation in sepsis patients, and prognosis in septic acute kidney injury patients: A pilot study. BMC Nephrol. 2021, 22, 219. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Shimoyama, Y.; Umegaki, O.; Kadono, N.; Minami, T. Presepsin Values Predict Septic Acute Kidney Injury, Acute Respiratory Distress Syndrome, Disseminated Intravascular Coagulation, and Shock. Shock 2021, 55, 501–506. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.Y.; Hong, D.Y.; Kim, J.W.; Park, S.O.; Lee, K.R.; Baek, K.J. Predictive Values of Procalcitonin and Presepsin for Acute Kidney Injury and 30-Day Hospital Mortality in Patients with COVID-19. Medicina 2022, 58, 727. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kim, S.Y.; Hong, D.Y.; Lee, K.R.; Paik, J.H.; Jung, H.M. Plasma presepsin level predicts acute kidney injury in patients with sepsis in the emergency department. Medicine 2022, 101, e29919. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Shimoyama, Y.; Umegaki, O.; Kadono, N.; Minami, T. Presepsin and platelet to lymphocyte ratio predict the progression of septic subclinical acute kidney injury to septic acute kidney injury: A pilot study. BMC Res. Notes 2022, 15, 212. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Shimoyama, Y.; Kadono, N.; Umegaki, O. Presepsin is a more useful predictor of septic AKI and ARDS for very-old sepsis patients than for young sepsis patients in ICUs: A pilot study. BMC Res. Notes 2024, 17, 53. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Isaranuwatchai, S.; Sophonphan, J.; Voharnsuchon, P.; Thong-on, K.; Sri-on, J. Presepsin and procalcitonin levels are associated with acute kidney injury in sepsis patients. Nephrol. Dial. Transplant. 2024, 39 (Suppl. S1), gfae069–1117. [Google Scholar] [CrossRef]
- Resolução nº 510, de 07 de abril de 2016—Conselho Nacional de Saúde. Available online: https://www.gov.br/conselho-nacional-de-saude/pt-br/atos-normativos/resolucoes/2016/resolucao-no-510.pdf/view (accessed on 10 July 2025).
- Formenti, P.; Gotti, M.; Palmieri, F.; Pastori, S.; Roccaforte, V.; Menozzi, A.; Galimberti, A.; Umbrello, M.; Sabbatini, G.; Pezzi, A. Presepsin in Critical Illness: Current Knowledge and Future Perspectives. Diagnostics 2024, 14, 1311. [Google Scholar] [CrossRef]
- Imagawa, A.; Uozumi, E.; Shiota, Y.; Shiraishi, R.; Ikezawa, A.; Morita, S. Presepsin level in renal dysfunction and hemodialysis patients. J.-Global. 2015, 64, 169–172. [Google Scholar]
- Russell, J.A. Management of sepsis. N. Engl. J. Med. 2006, 355, 1699–1713. [Google Scholar] [CrossRef]
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Birkelo, B.C.; Pannu, N.; Siew, E.D. Overview of Diagnostic Criteria and Epidemiology of Acute Kidney Injury and Acute Kidney Disease in the Critically Ill Patient. Clin. J. Am. Soc. Nephrol. 2022, 17, 717–735. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Smith, T.D.; Soriano, V.O.; Neyra, J.A.; Chen, J. Identifying KDIGO Trajectory Phenotypes Associated with Increased Inpatient Mortality. In Proceedings of the 2019 IEEE International Conference on Healthcare Informatics (ICHI), Xi’an, China, 10–13 June 2019. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Tsujimoto, K.; Hata, A.; Fujita, M.; Hatachi, S.; Yagita, M. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int. J. Rheum. Dis. 2018, 21, 1406–1413. [Google Scholar] [CrossRef] [PubMed]
- Scherberich, J.E.; Nockher, W.A. CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Clin. Chem. Lab. Med. 1999, 37, 209–213. [Google Scholar] [CrossRef] [PubMed]
- Larsen, B.; Hoff, G.; Wilhelm, W.; Buchinger, H.; Wanner, G.A.; Bauer, M. Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 1998, 89, 1218–1227. [Google Scholar] [CrossRef] [PubMed]
- Piacevoli, Q.; Karan, R.; Mascia, A. Presepsin: A New Biomarker for Sepsis? Prim. Sci. Med. Public Health 2023, 2, 11–34. [Google Scholar] [CrossRef]
- Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; Mcintyre, L.; Ostermann, M.; Prescott, H.C.; et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit. Care Med. 2021, 49, e1063–e1143. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.C.; Lan, H.M.; Han, S.T.; Chaou, C.H.; Yeh, C.F.; Liu, S.H.; Li, C.H.; Blaney, G.N., 3rd; Liu, Z.Y.; Chen, K.F. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: A systematic review and meta-analysis. Ann. Intensive Care 2017, 7, 91. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Oikonomakou, M.Z.; Gkentzi, D.; Gogos, C.; Akinosoglou, K. Biomarkers in pediatric sepsis: A review of recent literature. Biomark. Med. 2020, 14, 895–917. [Google Scholar] [CrossRef] [PubMed]
Number | Authors | Year | Country | Type | Population | Outcomes | ||||
---|---|---|---|---|---|---|---|---|---|---|
Sensibility | Specificity | AUC | Mortality | Cutoff (pg/mL) | ||||||
1 | Takahashi, G., Shibata, S., Fukui, Y., Okamura, Y. & Inoue, Y. [52] | 2016 | Japan | Retrospective | 91 | 0.69 | 0.79 | 0.84 | - | 891 |
2 | Shimoyama, Y., Umegaki, O., Kadono, N. & Minami, T. [53] | 2021 | Japan | Prospective | 83 | 0.82 | 0.77 | 0.77 | - | 1373 |
3 | Shimoyama, Y., Umegaki, O., Kadono, N. & Minami, T. [54] | 2021 | Japan | Prospective | 83 | 0.82 | 0.59 | 0.73 | 31.3% | 708 |
4 | Kim, S.Y., Hong, D.Y., Kim, J.W., Park, S.O., Lee, K.R. & Baek, K.J. [55] | 2022 | Korea | Retrospective | 151 | 0.66 | 0.691 | 0.700 | 12.6% | 572 |
5 | Kim, S.Y., Hong, D.Y., Lee, K.R., Paik, J.H. & Jung, H.M. [56] | 2022 | Korea | Prospective | 193 | 0.77 | 0.817 | 0.793 | 14% | 572 |
6 | Shimoyama, Y., Umegaki, O., Kadono, N. & Minami, T. [57] | 2022 | Japan | Prospective | 59 | 0.82 | 0.52 | 0.69 | 42% | 708 |
7 | Shimoyama, Y., Kadono, N. & Umegaki, O. [58] | 2024 | Japan | Prospective | 83 | 0.95 | 0.53 | 0.71 | 31.3% | 627 |
8 | Isaranuwatchai, S., Sophonphan, J., Voharnsuchon, P., Thong-on, K. & Sri-on, J. [59] | 2024 | Thailand | Prospective | 246 | - | - | - | 24% | 795 |
9 | Puspitasari, S., Semedi, B.P., Rehatta, N.M., Maulydia, M. & Purnomo, W. [30] | 2025 | Indonésia | Prospective | 56 | 0.581 | 0.625 | 0.595 | 64.29% | - |
Database | PubMed | Web of Science | Embase | Scopus |
---|---|---|---|---|
Number of references | 12 | 35 | 58 | 25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moura, E.L.B.d.; Ferreira, D.P.; Pereira, R.W. Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence. J. Clin. Med. 2025, 14, 6970. https://doi.org/10.3390/jcm14196970
Moura ELBd, Ferreira DP, Pereira RW. Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence. Journal of Clinical Medicine. 2025; 14(19):6970. https://doi.org/10.3390/jcm14196970
Chicago/Turabian StyleMoura, Edmilson Leal Bastos de, Dilson Palhares Ferreira, and Rinaldo Wellerson Pereira. 2025. "Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence" Journal of Clinical Medicine 14, no. 19: 6970. https://doi.org/10.3390/jcm14196970
APA StyleMoura, E. L. B. d., Ferreira, D. P., & Pereira, R. W. (2025). Presepsin as a Diagnostic and Prognostic Biomarker of Sepsis-Associated Acute Kidney Injury: A Scoping Review of Clinical Evidence. Journal of Clinical Medicine, 14(19), 6970. https://doi.org/10.3390/jcm14196970